It was previously reported that pristimerin down-regulated MMP2 and matrix metallopeptidase 9 (MMP9) to inhibit migration and invasion of esophageal squamous cell carcinoma (ESCC) 32. This evidence concerns the gene MMP2 and esophageal squamous cell carcinoma.